Confo Therapeutics appoints Paolo Vicini as Chief Development Officer

- 03/06/2020

New management role underscores Company’s commitment to establishing and advancing its proprietary pipeline of GPCR modulating drug candidates

Ghent, Belgium: 3 June 2020 – Confo Therapeutics today announced the appointment of Paolo Vicini, PhD, MBA, in the newly-created position of Chief Development Officer (CDO) effective June 1, 2020. With two decades of leadership and scientific experience in pharmaceutical research and development, Dr. Vicini joins Confo from his most recent position as Vice President, Development Sciences at Kymab. At Confo, he will apply his experience in translational and clinical sciences to support the Company as it moves its GPCR modulating small molecules through preclinical studies and into the clinic. He will be based at the Company’s headquarters in Ghent, Belgium and report to the CEO.

More info on Confo Therapeutics’ website.